Want to see GB:VAL full AI Analyst Report?
VAL Stock Chart & Stats
0.16 p
<0.01 p(1.56%)
At close: 4:00 PM EDT
0.16 p
<0.01 p(1.56%)
Day’s Range― - ―
52-Week Range0.13 p - 0.80 p
Previous CloseN/A
Volume993.58K
Average Volume (3M)8.30M
Market Cap
£1.85M
Enterprise Value0.23 p
Total Cash (Recent Filing)£791.61K
Total Debt (Recent Filing)£1.40K
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Sep 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,320,301,000
10 Day Avg. Volume4,392,582
30 Day Avg. Volume8,296,509
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.49
Price to Sales (P/S)44.16
P/FCF Ratio-0.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt reduces financial risk and avoids significant interest or refinancing pressure. This gives ValiRx greater flexibility to direct available resources toward its therapeutic pipeline, although low leverage does not eliminate the need to fund ongoing losses.
Partnering-Based Business ModelAn out-licensing model can monetize drug candidates without requiring ValiRx to build a full commercial infrastructure. Successful partnerships could provide milestone payments and future royalties, creating potential operating leverage if pipeline assets attract counterparties.
Focused Therapeutic PipelineConcentration in oncology and women’s health gives the company a defined scientific and commercial focus rather than a broad, unfocused portfolio. Advancing candidates through development may create partnering opportunities if programs demonstrate sufficient therapeutic value.
Bears Say
Declining RevenueRevenue remains extremely small relative to the company’s cost base and declined materially year over year. This indicates that current commercial monetization is not yet sufficient to support operations, leaving results dependent on future licensing or development progress.
Persistent LossesSustained operating and net losses show that the business has not reached economic breakeven. Continued losses can consume capital, weaken financial resilience and make future value creation increasingly dependent on successful clinical advancement or partnering transactions.
Structural Cash BurnNegative operating and free cash flow means the company is not currently self-funding its activities. Ongoing cash burn creates recurring funding needs and can constrain pipeline investment, while external financing may dilute existing holders or depend on market access.
ValiRx plc News
VAL FAQ
What was ValiRx PLC’s price range in the past 12 months?
ValiRx PLC lowest share price was 0.13 p and its highest was 0.80 p in the past 12 months.
What is ValiRx PLC’s market cap?
ValiRx PLC’s market cap is £1.85M.
When is ValiRx PLC’s upcoming earnings report date?
ValiRx PLC’s upcoming earnings report date is Sep 08, 2026 which is tomorrow.
How were ValiRx PLC’s earnings last quarter?
ValiRx PLC released its earnings results on Jun 22, 2026. The company reported -0.003 p earnings per share for the quarter.
Is ValiRx PLC overvalued?
According to Wall Street analysts ValiRx PLC’s price is currently Overvalued.
Does ValiRx PLC pay dividends?
ValiRx PLC does not currently pay dividends.
What is ValiRx PLC’s EPS estimate?
ValiRx PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ValiRx PLC have?
ValiRx PLC has 1,320,301,000 shares outstanding.
What happened to ValiRx PLC’s price movement after its last earnings report?
ValiRx PLC reported an EPS of -0.003 p in its last earnings report. Following the earnings report the stock price went down -8.108%.
Which hedge fund is a major shareholder of ValiRx PLC?
Currently, no hedge funds are holding shares in GB:VAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ValiRx PLC
ValiRx plc is a UK-based biopharmaceutical company dedicated to pioneering oncology therapeutics and companion diagnostics. Among its primary drug candidates is VAL201, a small molecule that has progressed through Phase I/II trials, aiming to treat prostate cancer and other hormone-dependent solid tumors, including breast and ovarian cancer. Another key candidate, VAL401, a reimagined version of the antipsychotic drug risperidone, has successfully completed Phase II clinical trials for addressing non-small cell lung cancer. The company's pipeline also features VAL301, a peptide currently in pre-clinical development for treating endometriosis in women. Additionally, BC201, a compound combining the peptide ingredient from VAL201/VAL301 with complementary active components, is being developed to alleviate severe symptoms of COVID-19. ValiRx plc was established in 2000 and is headquartered in Hatfield, United Kingdom.
Technical Analysis
Evgen Pharma
―
ImmuPharma
―
Sareum Holdings
―
Scancell Holdings
―
HemoGenyx Pharmaceuticals Plc
―